secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2023-01-04T23:59:59+00:00
Accession:  0001437749-23-000218
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva reports 40% enrollment in Phase 3 schizophrenia trial; top-line data expected mid-2023
--------------------------------------------------------------------------------

- About 40% of patients treated in pivotal Phase 3 RECOVER trial of brilaroxazine; no treatment-related SAEs.
- Top-line data from Phase 3 trial expected mid-2023; NDA submission planned if positive, potential commercial launch in 2025.
- Completed DDI study for brilaroxazine; results indicate advantage over other antipsychotics regarding drug interactions.
- Raised $8.5M in September 2022 from registered direct offering and private placement; improved financial position.
- Exploring non-dilutive financing and partnerships to expand brilaroxazine into bipolar, MDD, ADHD, PAH, IPF; combined market >$70B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923000218/0001437749-23-000218-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923000218/rvph20230102_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-000218

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer